Nucleus, ASTCT News

ASTCT Special Interest Group Member Spotlight: Zainab Shahid, MD, MPH, FACP, FIDSA

Zainab Shahid, MD, MPH, FACP, FIDSA, serves as chair of American Society for Transplantation and Cellular Therapy’s (ASTCT) Infectious Diseases Special Interest Group (SIG) and is a recognized leader in the prevention and management of infections among transplantation and cellular therapy recipients.

In this Special Interest Group Member Spotlight, Dr. Shahid reflects on her path into transplant infectious diseases, the collaborations and experiences that have shaped her career, and the evolving infection-related challenges facing patients receiving transplantation and cellular therapies. She also discusses the growth of ASTCT’s Infectious Diseases SIG, lessons learned through her research journey, and the importance of collaboration in advancing patient care and outcomes.

Nucleus: What inspired you to pursue a career as an infectious disease specialist focusing on infection in cellular and transplantation therapies?

Zainab Shahid, MD, MPH, FACP, FIDSA (ZS): Infections are a major cause of morbidity and mortality in immunocompromised patients, and they often present very differently than in immunocompetent hosts, a complexity that sparked my curiosity early in my training.

Since fellowship, my clinical practice and research have focused on improving outcomes for patients receiving novel cellular therapies because their success depends on protecting patients during their most vulnerable periods.

As therapies like CAR T-cell therapy expand, new questions keep arising about immune reconstitution, novel toxicities, and emerging pathogens. That constant evolution keeps me energized and carries a responsibility to make sure these patients are protected for short- and long-term infection.

Nucleus: What motivated you to engage with ASTCT, and how has that involvement supported your work in research and patient care?

ZS: I’ve attended the Tandem Meetings since fellowship, drawn by my research interest in infections in transplant and cellular therapy recipients.

Over the years, I’ve worked with many ASTCT and Center for International Blood and Marrow Transplant Research (CIBMTR) members in different capacities, and that involvement deepened during the COVID-19 pandemic, when collaboration across centers became essential to care for our most vulnerable patients.

Those connections have shaped my research and directly informed the care I provide patients, giving me access to shared data, practical guidance, and colleagues working through the same challenges.

Nucleus: What are some of the big wins for the SIG since you assumed the role of Transplant Infectious Disease Chair in 2025?

ZS: Our Transplant Infectious Diseases (TID) SIG has grown tremendously over the past few years, and I’m excited to build on that momentum.

Our research subcommittee is leading a multi-institutional effort to address outstanding questions about rare infections in cellular therapy recipients, while our education subcommittee has produced resources for the broader ASTCT community. This progress is possible because of our dedicated volunteers, whose efforts continue to advance ASTCT’s mission.

This year, I’m especially looking forward to launching the inaugural TID SIG Lifetime Achievement Award to recognize a leader whose hard work and commitment has moved our field forward. (Learn more about ASTCT’s Awards)

Nucleus: What are the most important lessons you’ve learned over the course of your research career?

ZS:

  • The best research questions come from the bedside.
  • Collaborations multiples impact.
  • It’s a marathon, not a sprint.
  • Persistence matters; stay curious.

Nucleus: Outside of your work, what's something you enjoy doing that might surprise your colleagues or ASTCT members?

ZS: Believe it or not, my mind isn’t always on bugs and the immune system!

When I step away from work, you’ll find me flowing through yoga, getting in a good lift, exploring somewhere new, or slowing down with the perfect cup of chai.

Learn more about ASTCT’s SIGS and membership today.